Drug Research

Biotech Future: Emerging Drug Methods And Industry Shifts

Innovative drug methods are causing a big change in the biotech industry, especially in cancer, where complicated diseases are treated. This change includes personalized medicines, treatments that work together, and new ways to get products to patients. As the...

Small Molecule API Market Growth Analysis and Future Trends

Small Molecule API Market Size, Share, and Growth Analysis The world's healthcare sector is experiencing an increase in demand for high-quality, dependable pharmaceutical ingredients, led by the quickening pace of progress in small molecule Active Pharmaceutical Ingredients (APIs). Being the...

Reviving Old Drugs with Specialty Intermediates in Europe

Drug development in the European pharmaceutical industry is undergoing a dramatic shift, largely due to the repurposing and reformulation of pre-existing chemicals rather than the discovery of novel molecules.   Advances in specialty intermediates, which are essential for repurposing...

Specialty Chemicals Solubility Enhances Drug Formulations

The need to improve the effectiveness, safety, and accessibility of drugs drives research and innovation in the ever-evolving pharmaceutical industry.  The problem of solubility and bioavailability, which affect how well a medication reaches its intended biological target after oral...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2 RAINFOL-01 trial of rinatabart sesutecan (Rina-S®), an experimental folate receptor-alpha (FRα)-targeted, TOPO1 antibody-drug combination (ADC). Data from the B1 cohort of the trial showed encouraging antitumor efficacy in highly pre-treated...

Revolutionizing Pharma Manufacturing with Biofermentation

Synthetic Chemistry and Integrated Biofermentation Transformational Pharmaceutical Manufacturing Combining biofermentation with chemical synthesis is shown to be creative in the realm of pharmaceutical manufacturing.  Following industry sustainability and innovation goals, this modern approach raises manufacturing process efficiency.  Businesses, researchers, and...

LINDIS Biotech Partners with Celonic for Production and Commercial Supply of Catumaxomab

LINDIS Biotech has received EMA Marketing Authorisation for catumaxomab, making it the only medicine licensed for the targeted and cancer-directed therapy of malignant ascites. Celonic Group will produce catumaxomab for commercial use. Catumaxomab will be manufactured at Celonic's...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read